Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Agios Pharmaceuticals (NQ: AGIO )

30.18 +0.62 (+2.10%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 531,887
Open 29.88
Bid (Size) 28.85 (1)
Ask (Size) 30.79 (4)
Prev. Close 29.56
Today's Range 29.50 - 30.76
52wk Range 16.75 - 34.76
Shares Outstanding 58,951,469
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
3 Under-the-Radar Biotech Stocks to Buy in 2022
The attraction of all three biotech stocks is their potential. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For November 17, 2022
Upgrades 
Via Benzinga

Performance

YTD
+9.63%
+9.63%
1 Month
+9.63%
+9.63%
3 Month
+8.48%
+8.48%
6 Month
+20.96%
+20.96%
1 Year
-6.16%
-6.16%

More News

Read More
Agios Pharmaceuticals's Return On Capital Employed Overview
Via Benzinga
Looking Into Agios Pharmaceuticals Return On Capital Employed
Via Benzinga
Agios Is Looking For Development Partner, Lays Off Exploratory Research Staff
Via Benzinga
7 Analysts Have This to Say About Agios Pharmaceuticals
Via Benzinga
Europe Approves Agios Pharma's Mitapivat For Adult Pyruvate Kinase Deficiency Patients
Via Benzinga
Agios Pharmaceuticals: Q3 Earnings Insights
Via Benzinga
Agios Pharmaceuticals Stock Clears Key Benchmark, Hitting 90-Plus RS Rating
Via Investor's Business Daily
Nutanix, Five Below And Some Other Big Stocks Moving Higher On Thursday
Via Benzinga
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate
Via Benzinga
Agios Pharmaceuticals: Q1 Earnings Insights
Via Benzinga
Why Snap Shares Jumped 7%; Here Are 75 Biggest Movers From Yesterday
Via Benzinga
Agios Pharmaceuticals: Q2 Earnings Insights
Via Benzinga
Why Okta Is Trading Lower By Over 32%, Here Are 58 Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 27, 2022
Via Benzinga
The Daily Biotech Pulse: AstraZeneca's COVID-19 Vaccine As Effective As mRNA Shots, Humanigen's Lenzilumab Disappoints In COVID-19 Study, Positive Preclinical Data From Hoth's Alzheimer's Program
Via Benzinga
U.S. Stock Futures Higher; All Eyes On Inflation Data
Via Benzinga
Delta Air Lines, Fastenal And 3 Stocks To Watch Heading Into Wednesday
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates
Via Benzinga
The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company
Via Benzinga
Analyst Ratings For Agios Pharmaceuticals
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.